Merit Medical's WRAPSODY WAVE Trial Demonstrates Patency Vs. Standard Of Care In AV Fistula Patients
Portfolio Pulse from Benzinga Newsdesk
Merit Medical Systems, Inc. (NASDAQ:MMSI) announced positive results from its WRAPSODY WAVE trial, showing superior patency in AV fistula patients compared to standard care. The trial demonstrated a 27% higher patency rate for WRAPSODY over percutaneous transluminal angioplasty.
September 16, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merit Medical's WRAPSODY WAVE trial results show a significant improvement in AV fistula patency compared to standard care, potentially boosting the company's market position and stock price.
The trial results indicate a significant improvement in treatment efficacy, which could enhance Merit Medical's competitive edge and lead to increased adoption of WRAPSODY. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100